|
| 產(chǎn)地 | 進(jìn)口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號(hào) | CS11082 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 |
| CAS編號(hào) | |
| 抗體名 | Anti-RFC2 |
| 克隆性 | |
| 靶點(diǎn) | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標(biāo)識(shí)物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human RFC2 |
產(chǎn)品訂購信息：
英文名稱 Anti-RFC2
中文名稱 復(fù)制激活因子C2抗體規(guī)格
別 名 Activator 1; Activator 1 subunit 2; Activator 140 kDa Subunit; MGC3665; OTTHUMP00000160645; OTTHUMP00000160646; replication factor C (activator 1) 2 40kDa; Replication factor C (activator 1) 2; Replication factor C 2; Replication Factor C 40 kDa subunit; Replication factor C subunit 2; replication factor c2; Replication Factor C40 kDa subunit; RF C 40 kDa subunit; RF-C 40 kDa subunit; RFC 2; RFC 40; RFC 40 kDa subunit; RFC2; RFC2_HUMAN; RFC40; A1 40 kDa subunit; A1 antibody A140; Activator 1 40 kDa Subunit.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Dog, Pig, Cow, Horse, Sheep
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 細(xì)胞凋亡 表觀遺傳學(xué)
蛋白分子量 predicted molecular weight: 39kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human RFC2
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
復(fù)制激活因子C2抗體規(guī)格 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 Replication factor C (RFC) is an essential DNA polymerase accessory protein that is required for numerous aspects of DNA metabolism including DNA replication, DNA repair, and telomere metabolism. RFC is a heteropentameric complex that recognizes a primer on a template DNA, binds to a primer terminus, and loads proliferating cell nuclear antigen (PCNA) onto DNA at primer-template junctions in an ATP-dependent reaction. All five of the RFC subunits share a set of related sequences (RFC boxes) that include nucleotide-binding consensus sequences. Four of the five RFC genes (RFC1, RFC2, RFC3, and RFC4) have consensus ATP-binding motifs. The small RFC proteins, RFC2, RFC3, RFC4 and RFC5, interact with Rad24, whereas the RFC1 subunit does not. RFC2, the third-largest subunit of the RFC complex, exhibits ATP binding which makes it important for both DNA replication and checkpoint function. The human RFC2 gene maps to chromosome 7q11.23 and encodes the RFC2 subunit. RFC2 has been associated with Williams-Beuren syndrome, which is a rare multi-system developmental disorder caused by the deletion of contiguous genes at 7q11.23.
Function : The elongation of primed DNA templates by DNA polymerase delta and epsilon requires the action of the accessory proteins proliferating cell nuclear antigen (PCNA) and activator 1. This subunit binds ATP.
Subunit : Heterotetramer of subunits RFC2, RFC3, RFC4 and RFC5 that can form a complex either with RFC1 or with RAD17. The former interacts with PCNA in the presence of ATP, while the latter has ATPase activity but is not stimulated by PCNA. RFC2 also interacts with PRKAR1A; the complex may be involved in cell survival.
Subcellular Location : Nucleus.
DISEASE : Note=RFC2 is located in the Williams-Beuren syndrome (WBS) critical region. WBS results from a hemizygous deletion of several genes on chromosome 7q11.23, thought to arise as a consequence of unequal crossing over between highly homologous low-copy repeat sequences flanking the deleted region.
Similarity : Belongs to the activator 1 small subunits family.
Database links : UniProtKB/Swiss-Prot: P35250.3
Anti-ABCA1/FITC 熒光素標(biāo)記腺苷三磷酸結(jié)合盒轉(zhuǎn)運(yùn)體A1抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Anti-EDG4/LPA2/FITC 熒光素標(biāo)記溶血磷脂酸受體蛋白2抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh CTAGE6 CTAGE6蛋白抗體 規(guī)格 0.2ml
Melamine/BSA 三聚氰胺與血清白蛋白偶聯(lián)物 1mg
ZFP103 英文名稱： 鋅指蛋白103抗體 0.2ml
Rhesus antibody Rh VEGF-D 內(nèi)皮生長因子D型抗體 規(guī)格 0.1ml
Anti-EDG4/LPA2/FITC 熒光素標(biāo)記溶血磷脂酸受體蛋白2抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Anti-TSARG7/FITC 熒光素標(biāo)記發(fā)生相關(guān)的新基因抗體IgGMulti-class antibodies規(guī)格： 0.2ml
TGF- Beta3 (Ttansforming Growth Factor – Beta3) 轉(zhuǎn)移生長因子–β3(抗原)Multi-class antibodies規(guī)格： 0.5mg
波形蛋白抗體 Anti-Vimentin 0.1ml
Phospho-SMC1(Ser957) 英文名稱： 磷酸化染色體結(jié)構(gòu)維持蛋白質(zhì)1抗體 0.1ml
ESM1 英文名稱： 內(nèi)皮細(xì)胞特異性分子1抗體 0.1ml
Rhesus antibody Rh phospho-IKK gamma(Ser43) 磷酸化KB抑制蛋白激酶γ抗體 規(guī)格 0.1ml
TGF- Beta3 (Ttansforming Growth Factor – Beta3) 轉(zhuǎn)移生長因子–β3(抗原)Multi-class antibodies規(guī)格： 0.5mg
Sin3b 英文名稱： 轉(zhuǎn)錄抑制蛋白Sin3b抗體 0.2ml
eEF1A2 英文名稱： 翻譯延伸因子EF-1 α2抗體 0.2ml
α-輔肌動(dòng)蛋白4抗體 Anti-α-ACTN4 0.1ml
Anti-HAS/RBITC 紅色羅丹明標(biāo)記人血清白蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh Phospho-FGFR1(Tyr653/654) 磷酸化堿性成纖維細(xì)胞生長因子受體1抗體 規(guī)格 0.1ml
CRMP2/Dpysl2(collapsin response mediator protein-2) 二氫嘧啶酶樣2CRMP2抗原Multi-class antibodies規(guī)格： 0.5mg
CTF1 Protein Human 重組人 Cardioophin-1 / CTF1 蛋白 (Fc 標(biāo)簽)
JM 人急性T淋巴細(xì)胞細(xì)胞
HA Others Influenza B 乙型 (B/Brisbane/60/2008) 血凝素HA1 (Hemagglutinin) 人細(xì)胞裂解液 (陽性對(duì)照)
LNCaP clone FGC人細(xì)胞 LNCaP clone human prostate cancer cell FGC RPMI-1640(GIBCO)+10%FBS
敘利亞倉鼠腎細(xì)胞;BHK-21
小鼠顆粒神經(jīng)元(MGC)(1×106) 6-10B, 人細(xì)胞系 Human
CL-0346HBE(人上皮樣細(xì)胞)5×106cells/瓶×2
DMT1 Others Human 人 DNMT2 / DMT1 桿狀病毒-昆蟲細(xì)胞裂解液 (陽性對(duì)照)
人肺泡上皮細(xì)胞總RNAHPAEpiC NA
K562細(xì)胞，慢性髓原 人胚肺二倍體細(xì)胞,HLF-02細(xì)胞 lovo, 人細(xì)胞
豹貓肺成纖維樣細(xì)胞;LCL1
HA Others H5N1 甲型 H5N1 (A/Anhui/1/2005) 血凝素 (Hemagglutinin / HA) 人細(xì)胞裂解液 (陽性對(duì)照)
復(fù)制激活因子C2抗體規(guī)格 CTF1 Protein Human 重組人 Cardioophin-1 / CTF1 蛋白 (Fc 標(biāo)簽)
JM 人急性T淋巴細(xì)胞細(xì)胞
HA Others Influenza B 乙型 (B/Brisbane/60/2008) 血凝素HA1 (Hemagglutinin) 人細(xì)胞裂解液 (陽性對(duì)照)
LNCaP clone FGC人細(xì)胞 LNCaP clone human prostate cancer cell FGC RPMI-1640(GIBCO)+10%FBS
敘利亞倉鼠腎細(xì)胞;BHK-21
小鼠顆粒神經(jīng)元(MGC)(1×106) 6-10B, 人細(xì)胞系 Human
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：
1. 復(fù)制激活因子C2抗體規(guī)格 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及*基,也可與糖基共價(jià)結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用；
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定：
1）復(fù)制激活因子C2抗體規(guī)格 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力?？贵w的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。
|
|
|
|
|
